Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.

Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, Kosiborod M, Wanner C, Standl E

Cardiovasc Diabetol 20 (1) 75 [2021-03-31; online 2021-03-31]

The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 ( http://www.cvot.org ).

Type: Other

PubMed 33789663

DOI 10.1186/s12933-021-01254-1

Crossref 10.1186/s12933-021-01254-1

pii: 10.1186/s12933-021-01254-1
pmc: PMC8010779


Publications 7.1.2